Biogenix LLC

BioGenix grew out of the recognition that regenerative medicine presents hope to patients who suffer from diseases or injuries. BioGenix has a longstanding reputation for building and maintaining supportive relationships with clinicians. We are equally committed to providing high-quality allograft products to clinicians all over the world. BioGenix adheres to stringent guidelines per Current Good Manufacturing Practices (cGMP), Current Good Tissue Practice (cGTP), State Regulations, AATB guidelines, FDA requirements for Human Cells, and Cellular and Tissue-based Products (HCT/P). While the BioGenix products are produced in an FDA compliant laboratory, it has not been approved by the FDA for treatment effectiveness. BioGenix advances this mission with the world's most advanced umbilical cord allograft products. Realizing the intrinsic value of transparency, BioGenix is committed to consistently share cutting-edge studies about innovative therapies and life science principles that support the natural healing of the body. Our commitment to excellence serves as the foundation to our core operating ethos culminating in the best safety track record within the industry.